Podcasts about ons

“She's triple negative and has a very, very aggressive tumor. Instead of going on spring break that year, she sat in our chemo room and got chemo. Her friends from college are good to try to keep her involved and try to surround her and encourage her, but they're right now in very, very different spots in their lives. She's fighting for her life; her friends are fighting for the grade they get in a class—and that's different,” ONS member Kristi Orbaugh, MSN, NP, AOCN®, AOCNP®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about metastatic breast cancer in adolescent and young adult patients. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 354: Breast Cancer Survivorship Considerations for Nurses Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities Episode 307: AYAs With Cancer: Financial Toxicity Episode 300: AYAs With Cancer: End-of-Life Care Planning ONS Voice articles: ‘Cancer Ghosting' May Add Another Layer of Emotional Burden for Patients Discoveries in Race-Related Breast Cancer Biomarkers May Improve Precision Treatments What Is HER-2-Low Breast Cancer? What Oncology Nurses Need to Know About Supporting AYAs With Cancer ONS books: Guide to Breast Cancer for Oncology Nurses Oncology Nursing Forum articles: An Integrative Review of the Role of Nurses in Fertility Preservation for Adolescents and Young Adults With Cancer Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers ONS huddle cards: Altered Body Image Fertility Preservation Sexuality Other ONS resources: Breast Cancer Learning Library Fertility Preservation in Individuals With Cancer ONS Biomarker Database American Cancer Society's breast cancer resources American Society of Clinical Oncology continuing education resources Elephants and Tea Life, Interrupted Livestrong National Cancer Institute's breast cancer resources Stupid Cancer Young Survival Coalition To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we use ‘adolescent and young adult,' we're really talking about age 19–35. Some groups will say 15–39, but right around that age. When we think about that age, think about what all could be going on during those ages. Late teenagers, they may be going off to college, they may be graduating high school, trying to set up their own life, trying to become independent from mom and dad. If you're talking about early to mid 30s, you could be talking about young parents, young career folks. So, just setting that into place makes you realize this can be a very tumultuous time for folks.” TS 2:06 “Unfortunately, this group tends to have more aggressive subtypes. We see more triple-negative in this group. We see more hormone-negative, HER2-positive in this group. Normal breast cancer cells should be stimulated by hormone. They are stimulated by hormones. So when you have a breast cancer cell that is not driven by hormones, it's much more difficult to treat. We tend to see more aggressiveness in these tumors. We also see a higher incidence in non-Caucasian folks in this age group compared to the older age groups.” TS 4:53 “I think we have gotten much better about understanding the importance of fertility preservation and getting reproductive endocrinologists in, sooner rather than later. If we have earlier-stage cancers and we have patients that want to try to preserve eggs, preserve fertility, sperm banking. … If you have that time to talk to them—maybe a 21-year-old—the primary thing on her mind is not how many children she wants to have one day. Maybe she's not even thought about having kids yet. It's still a question you need to [ask]. Do you want to try to preserve fertility? Do you want to try to harvest some eggs? That's a conversation that needs to be had and is very, very important for that age group.” TS 10:35 “One thing that helps is if you can get them [into] reputable support groups with people their own age that are going through what they're going through. Someone else that doesn't have hair, someone else that isn't going to make it to the big board meeting or isn't going to get the promotion this year because they've had to take a medical leave. Someone else that understands it differently.” TS 16:47 “In breast cancer, many of those biomarkers just get reflexed. And what I mean by reflexed is a breast cancer pathology comes through, or a breast cancer specimen comes through, and it just automatically gets tested for X, Y, Z. HER2 and of course ER/PR. Now we understand that we don't just need to know whether they're HER2 positive or HER2 negative. We need to know: What is the IHC score? And even if the IHC score is zero, is there any membrane staining? And then we need to know what's their ESR1, their PTEN, their AKT, their PIK3CA. Those are so important to know.” TS 18:11 “I think it's important to try to remember what our priorities were when we were in our 20s—what our priorities were when we were starting out as young mothers or starting out our career. Because that's where these folks are. … I can't imagine in the midst of college, when I'm trying to be independent, to suddenly have to be at home and rely on my mom to take me to my chemo appointment. … So I think one really important bias is to remember where they are in the developmental stages of life. They're not 40-something. They haven't lived X amount of life, and we need to take a step back and try to remember when we were their age, what was important to us? Where were our priorities at that point? And then hear them when they're telling us what's important to them.” TS 29:22 “From a female standpoint … we frequently throw these patients into menopause or have early menopausal symptoms, and I think we forget how devastating that can be. … They now are at higher risk for osteopenia or osteoporosis. … And then we tell people, ‘Be as normal as possible, get back and do those normal things.' Well, they're in a relationship, and they want to be intimate [but] suddenly having sexual intercourse is incredibly painful. Or if it's not painful, sometimes they've just lost pure interest in that. They don't feel confident about their body. All of those things need to be addressed because patients are trying to live each day as normally as possible.” TS 31:55 

Welkom terug bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast aflevering schuift NOA VAHLE aan tafel bij PEPIJN, GIJS en ROGIERPABLO om speelronde 03 te bespreken! ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

“Policies help make sure that we're giving patients the right education and discharge instructions. Radiation doesn't end when the syringe is empty. Patients go home with potential radioactive exposure. They need to know how to protect their families, what precautions to take, and what healthcare providers can do if something goes wrong—like a spill, extravasation, or even a pregnant staff member who's involved in the care. This isn't just a documentation exercise. It's about making sure every part of the system speaks the same language when it comes to safety, handling, and patient care,” ONS member Ella-Mae Shupe, MSN, RN, OCN®, nursing practice and professional development specialist for radiation oncology at Johns Hopkins Health System Sydney Kimmel Cancer Center based in Baltimore, MD, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about creating and implementing radiopharmaceutical policies and procedures.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 22, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to implementing policies and procedures to support administration of radiopharmaceuticals for cancer treatment. Episode Notes   Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 347: Care Considerations for Radiopharmaceuticals and Theranostics in Patients With Cancer Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles Episode 104: How Radiation Affects All Areas of Oncology Nursing ONS Voice articles: New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals ONS Voice oncology drug reference sheets: Lutetium Lu 177 Dotatate Lutetium Lu 177 Vipivotide Tetraxetan Radium 223 Dichloride Sodium Iodide-131 ONS book: Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) ONS course: ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing article: Nursing Telemedicine Educational Encounters: Improved Patient Satisfaction in Radiation Therapy Clinics Other ONS resources: ONS Radiation Learning Library ONS Radiation Safety: In the Home Huddle Card ONS Radiopharmaceuticals Huddle Card Daily Med Lutathera® website for healthcare professionals Pluvicto® website for healthcare professionals Xofigo® website for healthcare professionals To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “[Lutetium lu 177 vipivotide tetraxetan] has shown so effective in clinical studies that the FDA recently approved expanded use, and it can now be given prior to chemotherapy.” TS 1:56 “There are typically three parts to a radiopharmaceutical. One is a radioisotope, which emits the radiation. The second is a targeting molecule, which directs the compound to a specific site. And the third is a linker that binds the isotope to the targeting molecules securely. The targeting molecule is usually a substance that binds specifically to receptors, antigens, or metabolic pathways that are overexpressed on cancer cells.” TS 2:08  “We have an interdisciplinary team involvement. There's a physicist, nurse, and provider that confirm lab values are within normal limits. The patient meets all the clinical and safety criteria for administration. Second is an IV placement where a nurse or clin tech starts the IV and verifies a strong blood return. This is critical to avoid extravasation, which can be harmful due to the vesicant-like nature of radiopharmaceuticals. And third, our patient voids immediately before the injection, which reduces bladder radiation dose. During the administration, our provider administers the radiopharmaceutical using a shielded syringe holder to reduce radiation exposure. The physicist remains present throughout the procedure. Lead aprons are worn by any team members close to the IV site, and then the Geiger counter is used by physics to measure ionizing radiation, which is done before, during, and after the procedure.” TS 3:28 “The policy we created doesn't just address general principles. It includes very specific guidance for both [radium 223 dichloride] and [lutetium lu 177 vipivotide tetraxetan]. That includes everything from determining patient eligibility to completing the treatment directive, confirming patient identity, verifying delivery parameters, documenting the treatment itself, and ensuring the treatment environment is appropriate and safe. We've also built in drug- specific practices because [radium 223 dichloride] and [lutetium lu 177 vipivotide tetraxetan] each come with their own considerations. This includes competencies for nursing, tailored patient education for each therapy, and an extravasation checklist that outlines what to do and who's responsible for tasks if infiltration occurs.”TS 11:24 “We created two separate versions [of an attestation model], one for clinical staff and one for non-clinical staff. Why include non-clinical staff? Because the risks extend beyond just the clinical team. What if environmental services comes in to clean and the patient has urinated on the floor? Or what if dietary delivers a tray and moves a urinal without knowing the risk? Or what if transport comes in and handles an incontinent brief without awareness? Each of these scenarios has potential for contamination and exposure. And that's exactly why education for all roles matter.” TS 15:22 “These are such an exciting treatment for our patients, that's not chemotherapy, that's not radiation, and their quality of life has been amazing. We have had patients coming in that could barely walk because of the pain from bone mets and after a few treatments, they're much better. We've had PSAs go from five, six hundreds down to 0.5, so we're seeing a lot of really good options for these patients and treatment.” TS 22:09  

What happens when a cybersecurity engineer walks into a fashion boutique? For Harish Chandramowli, it sparked an idea that's now helping small fashion brands save time, money, and sanity. A chance observation in a New York store became a mission to untangle problems in inventory, communication, and operations many brands struggle with. In this episode, I speak with Harish, founder of Flair Software, about how he went from working at Bloomberg and MongoDB to building a platform that fixes the messy back-office problems fashion brands face. Harish explains why seasonal inventory is a high-stakes game, how communication breakdowns can cost thousands, and why he built his solution to integrate with Shopify instead of competing against it. Tune in now to learn more. --- Listen to the podcast here: From Cybersecurity to Fashion Tech with Harish Chandramowli Welcome to Action's Antidotes, your antidote to the mindset that keeps you settling for less. We have a lot of technological advances, a lot of digital technology, and a lot of the efforts around it have been used primarily around digital products, primarily around some of the platforms and everything else, but there's also an aspect that I'm hopeful around that really takes some of the digital technology that we have and uses it to enhance the physical products and the actual life that we have outside of our computers in real life. My guest today, Harish Chandramowli, is the founder of Flaire Software and he has some interesting solutions for the fashion industry and other kind of inventory-related pursuits. ---   Harish, welcome to the program.   It's a pleasure to be here.    Thank you for joining us. Now, first of all, kind of have your feet in both worlds, whether it be kind of our technological world as well as the world of fashion, the world of some of these in-real-life types of pursuits. Tell me a bit about your story, where you started and how you came up with the idea, what you observed that led to Flaire Software.   Yeah. Just taking a step back, I am not from fashion industry. It's all pretty new to me. I did my master's in cyber security actually in Johns Hopkins, then I worked as security engineer in a bunch of very data-related platforms like Bloomberg, MongoDB. And MongoDB was my last gig where I primarily started as cloud security engineer but moved on to like an Atlas dedicated team where you see how lot of different people use databases. And, interestingly, there are a lot of retail companies using databases very heavily. That made me more and more curious on how software is being used in retail industry and why database is like one of the biggest line expenditures. On top of that, when I was looking into ERPs, Oracle is one of the biggest player in the ERP market, which made me even more curious on what this space is. What happens around here? Why is a database company spending so much on an ERP, on like a data workflow?    Yeah.   This kind of made me curious but, again, it was more like I don't think I was into fashion or any of those things. I went to this store called ONS in Soho. It's a great store you should check out if you are ever in like downtown area in New York.    What's the store called again?   ONS.   Okay.   Orange, Naples, San Diego. So if you go to Soho and like downtown in the fashion districts, you will notice a lot of these small, small brands which is not your typical H&Ms or Zara.   Yeah.    So I was there, I was actually listening to their team meetings, talking a lot with their founder. I was looking at how they are operating in the back office. The first thing that stood out to me is that fashion as a whole uses a lot of software. One aspect of it which we are all familiar with is designing the fashion, like the threading, modeling and like the cut and everything. Another easier to relate option is like e-commerce site, where you list,

Ukrainian President Volodymyr Zelenskyy and his European allies have met with Donald Trump for a charm offensive. Plus: Massive anti-war protests rock Israel, the ONS declares average rents in England to be unaffordable, and author Sally Rooney has been reported to the police over her support for Palestine Action. With Aaron Bastani and Tadhg Hickey.

Welkom terug bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast aflevering schuift THOMAS HOGELING aan tafel bij PEPIJN, GIJS en SNIJBOON om speelronde-02 te bespreken! ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delenwaar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

“At least some of the answer to these issues of compassion fatigue and burnout have to do making our practice environments the very, very best they can be so that nurses and other clinicians can really connect and care for patients in the ways that they want to be able to do that—and the patients need them to be able to do. I think there's a lot that is here already and will be coming, and I feel pretty optimistic about it,” ONS member Anne Gross, PhD, RN, NEA-BC, FAAN, senior vice president for patient care services and chief nursing officer at Dana-Farber Cancer Institute in Boston, MA, told ONS member Christine Ladd, MSN, RN, OCN®, NE-BC, member of the ONS 50th anniversary committee, during a conversation about burnout and compassion fatigue in oncology nursing. Ladd spoke with Gross and ONS member Tracy Gosselin, PhD, RN, NEA-BC, AOCN®, FAAN, senior vice president and chief nursing executive at Memorial Sloan Kettering Cancer Center in New York, NY, about the history of nurse well-being and how nurses and health systems are approaching it today. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: ONS 50th anniversary series Episode 315: Processing Grief as an Oncology Nurse Episode 292: What We Need to Do to Retain Today's Oncology Nursing Workforce Episode 291: Build a Sense of Belonging for Nurses and Patients Episode 264: Stop the Stressors and Improve Your Mental Health as a Nurse Episode 246: Create a Culture of Safety: Fair and Just Culture Episode 160: Build Innovative Staff Education Tools and Resources ONS Voice articles: Critical Event Debriefings Can Reduce Oncology Nurses' Risk of Compassion Fatigue and Burnout ONS Chapters and DNP Candidates Combine Forces to Support Oncology Nurse Well-Being Step Out of Reality With Virtual Breaks to Support Your Wellness at Work Clinical Journal of Oncology Nursing articles: Burnout and Well-Being: Evaluating Perceptions in Bone Marrow Transplantation Nurses Using a Mindfulness Application Engaging Nurse Residents Through Poetry Strategies to Mitigate Moral Distress in Oncology Nursing ONS Nurse Well-Being Learning Library ONS Communities ONS Chapters Connie Henke Yarbro Oncology Nursing History Center Oncology Nursing Foundation Resiliency Resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Gross: “I was on an oncology unit early in practice. And just like today, we were dealing with very sick patients. We were dealing with death and dying. We were administering very toxic treatments and really pushing a field forward in oncology. So there were similar challenges, but I think different from today. There weren't the kind of resources; there wasn't the body of work that's been done today around compassion fatigue and burnout, work-life balance, and things like that. There was not that body of literature and science like there is today. And so there was more of a grassroots kind of support building in the clinical environment that I think I experienced.” TS 2:35 Gosselin: “I think there's also a piece when we think about nurses in the work we do—we also have families. We have aging parents and children. And sometimes that burnout is multifactorial in that we have family obligations and other obligations that make it really hard. And for some people, they say work is their escape from some of that. Yet it's all hard to balance sometimes.” TS 8:09 Gosselin: “It's this question that people like Anne, myself, other chief nurses are saying. If we add this new technology, what are we going to take away? Do we need another alarm to ring to the phone or to their badge? How much can you ask people to do and not be distracted when they're at point of care delivering patient care? Technology should never be a distractor, nor should it tell us how to practice. The technologies we have today—I'm like, ‘Wow, I wish I had that when I started my career.' And yet there's also a double-edged sword to that. I think we have to balance when we think about care and care delivery.” TS 16:36 Gross: “There are so many resources, first of all, that ONS provides to all of us at all levels and in all points in our career and our path from novice to experts. And the needs, though, are the same. Whether you're a novice nurse or whether you're a very experienced nurse, you need to continue to learn and to get new information, and ONS is an incredible resource for that. … As I think both of us keep alluding to and emphasizing here, you also need that connection to other people. And that's what ONS provides—that opportunity to get connected to other people that might be working in some other part of the country or other part of the world but is dealing with similar things that you're dealing with. So it provides that opportunity, and then it also provides an opportunity to get involved. I think when you can get involved and be part of solving a problem, it doesn't then control you and you won't feel defeated by it.” TS 22:24

ONS ditches the recording studio again for Safe Summer Nights at West Minnehaha Recreation Center. Connecting with Mayor Carter, SPPD Chief Henry, and a host of partners and community for feedback! Check out more great episodes at f2fpodcastnetwork.comAlso, check the F2F Podcast Network on YouTube

Welkom terug bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast aflevering maakt aanwinst Rogier z’n officiële debuut en blikt hij samen met Snijboon, Tim en Gijs terug op de eerste speelronde. ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delenwaar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Send us a text1 Johannes 1:8-9 As ons beweer dat ons nie sonde het nie, bedrieg ons onsself en is die waarheid nie in ons nie. Maar as ons ons sondes bely – Hy is getrou en regverdig, Hy vergewe ons ons sondes en reinig ons van alle ongeregtigheid. Het jy al ooit ervaar hoe dit voel om 'n diep, donker geheim in jou hart rond te dra – iets wat jy gedoen het, iets wat verskriklik verkeerd was; iets waarvan niemand anders weet nie? Dit versmoor jou, dit verpletter jou.Ek ken daardie gevoel baie goed. Ja, ons weet diep in ons hart dat daardie verpletterende las veroorsaak word deur die feit dat ons weet dat ons dade uiteindelik gevolge het. Ons weet dat dit wat ons verkeerd gedoen het uiteindelik sal uitkom. Ons weet dat ons uiteindelik die prys sal moet betaal.Dis iets waaroor ons die afgelope week nogal baie saam oor gesels het, nè? So kom ons sluit dan met goeie nuus af; nuus, wat daardie bagasie wat jy saamdra, van jou skouers sal lig.1 Johannes 1:8-9 As ons beweer dat ons nie sonde het nie, bedrieg ons onsself en is die waarheid nie in ons nie. Maar as ons ons sondes bely – Hy is getrou en regverdig, Hy vergewe ons ons sondes en reinig ons van alle ongeregtigheid.Baie mense wil vandag gerieflikheidshalwe glad nie eers dink dat daar iets soos "sonde" bestaan nie. Maar God neem dit so ernstig op dat Hy sy Seun, Jesus, gestuur het om aan 'n kruis te sterf om die prys wat ons weet óns sonde verdien, te betaal.En wanneer jy eerlik met God is, wanneer jy jou sondes bely, sal Hy vergewe. Jy kan Hom vertrou om dit te doen, want Hy doen altyd wat Hy sê Hy sal. Hy sal jou reinig van al die verkeerde dinge wat jy gedoen het.My vriend, daardie vergifnis is vandag vir jou beskikbaar. Bely met ‘n opregte hart en met nederigheid én berou al jou sonde voor God; glo dat Jesus vir jou gesterf het en die vrede van God sal jou tot oorlopens vul. Dis goeie nuus.Want dis Sy Woord. Vars ... vir jou ... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

President Cyril Ramaphosa bring op Nasionale Vrouedag hulde aan die 20 000 vroue wat in 1956 na die Uniegebou opgeruk het. Ons fokus op Vrouedag, en hoor die stemme van verskeie formidabele vroue. Vroue in die rolprentbedryf sê daar is steeds poste wat hoofsaaklik deur mans beklee word.

Send us a text1 Petrus 1:17-19 En onthou dat die Vader tot wie julle bid, niemand voortrek wanneer Hy beoordeel nie. Hy beoordeel elke mens volgens sy dade. Daarom moet julle julle eerbied vir Hom wys met julle leefstyl, al is julle uitlanders. Julle weet mos dat God betaal het om julle los te koop van die sinlose leefstyl wat julle van julle voorouers oorgeërf het. En dié losprys was nie dinge wat vergaan, soos goud of silwer nie. Inteendeel, dit was die kosbare bloed van Christus, soos dié van 'n lam wat vlekloos en sonder liggaamsgebrek is. (NLV) Vir baie mense is vrees 'n konstante metgesel. Nou dink jy dalk: "Ek is vir niks bang nie." Dit klink baie dapper. Die vraag is, wat lê om die draai?Ons sien vrees, oor die algemeen, as 'n slegte ding ... en dit is dikwels. Maar vandag wil ek graag oor ‘n ‘goeie vrees' met jou gesels. Ons leer hoe God talle kere vir Israel tydens hul ballingskap uit hul verknorsing gered het. Maar weet jy, dit maak nie saak wat ons vandag mag konfronteer nie, God wil ons ook red. Hy wil ons van daardie slegte vrese vrymaak tot 'n ‘goeie vrees' of anders gestel, ‘n heilige ontsag vir Hom.1 Petrus 1:17-19 En onthou dat die Vader tot wie julle bid, niemand voortrek wanneer Hy beoordeel nie. Hy beoordeel elke mens volgens sy dade. Daarom moet julle julle eerbied vir Hom wys met julle leefstyl, al is julle uitlanders. Julle weet mos dat God betaal het om julle los te koop van die sinlose leefstyl wat julle van julle voorouers oorgeërf het. En dié losprys was nie dinge wat vergaan, soos goud of silwer nie. Inteendeel, dit was die kosbare bloed van Christus, soos dié van 'n lam wat vlekloos en sonder liggaamsgebrek is. (NLV)Die slegte dinge wat ons doen; die verkeerde dinge wat ons doen, is baie dikwels die oorsaak van die knaende vrese wat ons van binne-af opvreet. Kan ek dit openlik en kras stel? Sonde maak die deur vir vrees oop.Maar God het ons daarvan gered deur Jesus te stuur om aan 'n kruis te sterf, sodat ons vergewe kan word. Hy het die losprys betaal, Hy het ons vrygemaak.En nou verwag Hy dat ons Hom sal vrees, Hom sal respekteer, Hom sal eer. Dis 'n goeie vrees, want hierdeur ontdek jy 'n vrede en 'n vreugde wat jy nooit gedink het moontlik is nie. Vandag is die dag om God te vrees.Dis Sy Woord. Vars ... vir jou ... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

“We're really using these in many, many types of malignancies. But you can see this class of drug, these monoclonal antibodies, the small molecule inhibitors, being used in colorectal cancer, ovarian cancer, renal cell carcinoma, brain cancers, hepatocellular, non-small cell lung cancer, gynecologic malignancies, so lots of different types of cancers where we're seeing these drugs used,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the vascular endothelial growth factor (VEGF) inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 8, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of VEGF inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 161: Administer Bevacizumab Infusions With Confidence ONS Voice articles: Manage Afatinib's Adverse Events to Keep Patients on Treatment Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Fruquintinib Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing article: Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Cancer cells are known to secrete factors that cause the formation of new blood vessels, and tumors need blood vessels to supply themselves with nutrients so that they can grow and metastasize. A lot of tumors overexpress these factors, so they had more of this ability to create new blood vessels. You may hear that term somewhere neo vascularization. … And also these factors can increase the permeability of blood vessels, so making them kind of leaky blood vessels. … So the thought behind it is being able to block the ability for this new blood vessel formation and to decrease that leakiness or permeability of those blood vessels.” TS 2:07 “These are drugs that are tyrosine kinase inhibitors. These are oral, small molecule drugs that are acting intracellular, so they are working within the cell to bind and prevent that downstream signaling of producing more blood vessels. So we have a number of small molecule drugs that fall into this class. Many of them target multiple types of receptors, VEGF being included, but also a lot of these drugs have other targets.” TS 7:58 “I would really say, number one, something that we very commonly see with this drug class is hypertension. Giving you an example of bevacizumab—If we look at any grade hypertension, this can be up to 67% of patients, so very common toxicity really spanning all of these agents. So something that we need to be monitoring closely for.” TS 13:24 “With that impaired wound healing, keeping that in mind, as we are planning for this agent, for patients and even sometimes with the minor surgical procedures, maybe a need for a short hold, and even for something like a catheter placement. I know and some of the providers I work with have a preference for holding for a short period of time around that as well.” TS 20:15 “I think one big area, and we've seen some of this just recently, and particularly in the hepatocellular setting, we're seeing combinations of using the VEGF inhibitor class with immunotherapy. And so I think we're going to continue to see that evolve. Even hearing about some bispecific antibodies that are in development, where they are targeting VEGF as well as PD-L1, so getting the immunotherapy and VEGF effects.” TS 24:44

Ons wip na Israel en eerste minister Benjamin Netanyahu het in 'n onderhoud met Fox News gesê dat Israel van voornemens is om militêre beheer oor die Gaza-strook te neem. Hy het bygevoeg dat Israel dit uiteindelik aan Arabiese magte sal oorhandig wat dit behoorlik sal regeer. Netanyahu het gepraat direk voor 'n vergadering met sy sekuriteitskabinet. Hy is gevra of Israel Gaza wil oorneem. Luister self.

Nóg 'n kind wreed aangerand. Ons bespreek die omstrede podsending wat aanstootlike opmerkings teenoor Bruinmense gemaak het. Ons praat met 'n onderwyskenner oor die nuwe BELA-regulasies wat pas in die staatskoerant gepubliseer is vir openbare kommentaar.

Send us a textOpenbaring 22:12-13 Jesus sê toe weer: “Kyk, Ek kom gou! Ek bring die loon saam met My om elkeen te beloon vir wat hy gedoen het. Ek is die Alfa en die Omega, die Eerste en die Laaste, die Begin en die Einde. Dade het gevolge. Dis iets wat ons ouers ons probeer leer het toe ons grootgeword het. En hoe gouer ons daardie les geleer het, hoe gouer het die lewe sommer baie beter geword.As ek jou ewe skielik ‘n lekker opstopper gee, sou dit billik wees om te verwag dat ek gestraf behoort te word. En kom ons wees eerlik, jy sou wou hê dat ek moet gestraf moet word, want dit sou die regte ding wees om te doen.Jy het dalk opgemerk, dat ons in die afgelope paar dae op die beginsel dat "dade-gevolge-het" gefokus het. Daar is 'n baie goeie rede daarvoor. Ons ewigheid hang daarvan af. Hier is Jesus se woorde om ons van die erns van die saak bewus te maak:Openbaring 22:12-13 Jesus sê toe weer: “Kyk, Ek kom gou! Ek bring die loon saam met My om elkeen te beloon vir wat hy gedoen het. Ek is die Alfa en die Omega, die Eerste en die Laaste, die Begin en die Einde.Die lewe raak so besig en ons is so gefokus op alles wat op die oomblik rondom ons aan die gang is, dat ons heeltemal perspektief van die geheelprentjie verloor; die ewige prentjie; óns ewigheid.Maar Jesus is ewig – Hy is die Alfa en die Omega, die eerste en die laaste, die begin en die einde. En Hy kom terug. Wanneer? Binnekort! Wie weet hoe gou? Ons lewens kan vanaand van ons geëis word. Ons tyd hier op aarde kan môre verby wees. Jesus kan volgende Donderdag terugkeer.Daardie ‘binnekort' kan baie gouer kom as wat ons ooit in ons besigwees gedink het.Kyk, Ek kom gou en bring my loon saam met My, om elkeen te vergeld vir wat hulle gedoen het.Dis God se Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Send us a textOpenbaring 20:12 Ek het die dooies, groot en klein, voor die troon sien staan, en die boeke is oopgemaak. Daar is ook 'n ander boek oopgemaak, dit is die boek van die lewe. Die dooies is toe geoordeel volgens wat daar in die boeke geskrywe staan oor alles wat hulle gedoen het. Dit is vir my ‘n baie vreemde ding dat die gevaar van straf nie vir baie van die kriminele mense genoeg van ‘n afskrikmiddel is nie. Maar weet jy, die blote gedagte daaraan om voor 'n hof te moet verskyn en skuldig bevind te word aan 'n misdaad, is vir my genoeg van ‘n afskrikmiddel ... ‘n baie goeie afskrikmiddel om my wetsgehoorsaam te hou. Hoe voel jy oor straf as ‘n afskrikmiddel?Ek dink die meeste van ons sal saamstem dat dit 'n goeie ding is om 'n streng en billike regstelsel te hê; een waardeur die beskuldigde skuldig of onskuldig bevind en gestraf kan word. Ja, voorwaar 'n baie goeie ding.Ons weet ook dat selfs die beste regstelsels soms foute maak, maar kan jy jou die anargie voorstel as daar geen regstelsel was nie?En tog, as jy om jou rondkyk, lyk dit of sosiale anargie – mense wat skandelik optree; mense wat mekaar sleg behandel – hoogty vier. Kan ons dan hoop dat God se geregtigheid op 'n stadium sal seëvier? Ja, dit sal beslis!Die apostel Johannes het 'n kykie gekry in die werkinge van die hemel, en dit is wat hy geskryf het:Openbaring 20:12 Ek het die dooies, groot en klein, voor die troon sien staan, en die boeke is oopgemaak. Daar is ook 'n ander boek oopgemaak, dit is die boek van die lewe. Die dooies is toe geoordeel volgens wat daar in die boeke geskrywe staan oor alles wat hulle gedoen het.Die "dooies" waarna hy verwys, is diegene wie se name nie in die Boek van die Lewe gevind sal word nie. Diegene wat nie die geleentheid gebruik het om terwyl hulle op aarde geleef het, terug te keer na God en op Jesus te vertrou nie.Kan ek jou ernstig versoek: Moenie jou lewe verkwis nie. Moenie jou ewigheid verkwis nie.Dis God se Woord. Vars ... vir jou ... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Ons leven staat onder druk, we brengen uren per dag door op onze mobiel, en ondertussen worden we bedreigd door autocraten, techmiljardairs en populisten. Dat is de boodschap van ds. Ad van Nieuwpoort in zijn nieuwe boek. Presentator Margje Fikse gaat daarover in gesprek met ds. Ad van Nieuwpoort.

Welkom terug bij De Derde Helft. Na de koppies even leeg gemaakt te hebben zijn we terug. In deze aflevering blikt het vaste trio vooruit op de eerste speelronde. Precies zoals jullie van Gijs, Tim en Snijboon gewend zijn, maar dan (met) meer - namelijk Pepijn en RogierPablo - en vaker. ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delenwaar ze naar uitkijken in de aankomende speelronde.

Send us a textRomeine 2:5b-8 ....daardie dag wanneer God, die regverdige regter, almal sal oordeel volgens wat hulle gedoen het. Aan dié wat met volharding aanhou om goed te doen, en op hierdie manier streef na die toekomstige heerlikheid, eer en onsterflikheid wat Hy vir hulle weggebêre het, sal Hy die ewige lewe gee. Maar dié wat hardkoppig weier om die waarheid te gehoorsaam en toegee aan die ongeregtigheid, sal Hy in sy woede straf. (NLV) As ons mooi daaraan dink, besef ons dat liefdevolle gesinne die grondslag van menswees in die gemeenskap vorm. Sonder gesinne sal die samelewing ineenstort ... en dit verklaar heel moontlik die gemors waarin die wêreld vandag is.Natuurlik is nie elke kind geseën om groot te word in ‘n huisgesin waar hy omring word deur 'n liefdevolle, alhoewel onvolmaakte, moeder en vader nie. Gelukkig het ek in so ‘n huis grootgeword en is die opvoeding wat ek gehad het, iets wat ek vir ewig sal koester.Maar weet jy, daardie opvoeding het 'n bietjie ‘liefde met gevoel' oftewel tough love behels! Dit het dissipline behels. Dit het selfs van tyd tot tyd die kweperlat behels – nie dat dit iets is wat ek vandag sal voorstaan nie. Tog was my ouers vasbeslote om my te leer dat dade gevolge het.Ons liefdevolle God wil ook vir ons dissiplineer en gehoorsaamheid leer; want indien ons dit nie leer nie, sal dit ewige gevolge hê:Romeine 2: 5b-8 ....daardie dag wanneer God, die regverdige regter, almal sal oordeel volgens wat hulle gedoen het. Aan dié wat met volharding aanhou om goed te doen, en op hierdie manier streef na die toekomstige heerlikheid, eer en onsterflikheid wat Hy vir hulle weggebêre het, sal Hy die ewige lewe gee. Maar dié wat hardkoppig weier om die waarheid te gehoorsaam en toegee aan die ongeregtigheid, sal Hy in sy woede straf. (NLV)Sjoe, is dit werklik in die Bybel? Ja, dit is! Wat het geword van ‘n God van barmhartigheid en genade? Wel, Hy is steeds die God van barmhartigheid en genade, maar ons aanvaar of verwerp daardie barmhartigheid en genade, deur hoe ons leef. Aan diegene wat in gehoorsaamheid reageer, sal Hy die ewige lewe gee. Vir diegene wat in ongehoorsaamheid reageer, sal Hy met toorn en woede straf.Ja, my vriend, dade het inderdaad gevolge.Dis God se Woord. Vars ... vir jou ... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54

On this week's L&G Talks Asset Management, we cover how UK universities are creating a nexus for Private Markets investment. Our recent research covered this subject, and discussion focused on some of the key points it raised, along with potential investment implications. Our panel consisted of: Bill Page, Head of Real Estate Research, L&G Melissa Lockett, Investment Director, Investment & Place Partnerships, L&G You can listen on: Apple Podcasts, Audioboom and Spotify. This podcast is hosted by Nick Jardine, Content Manager – Private Markets, at L&G. It was recorded on 29 July, 2025. Sources: Beauhurst, Spotlight on Spinouts, 2024, L&G StuRents, Knight Frank, December 2024 HESA, 2025 L&G calculations form ONS workforce jobs data, 2025 London Economics/Universities UK – The impact of higher education sector on the UK economy, Aug 2023 For professional investors only. Capital at risk. 

Join Office of Neighborhood Safety in this episode as we celebrate Safe Summer Nights at St. Paul's El Rio Community Center! Today we are highlighting community, partnerships, and feedback. Check out more great episodes at f2fpodcastnetwork.comAlso, check the F2F Podcast Network on YouTube

Op het moment dat jullie dit luisteren bewaakt Gijsje het fort (de Saarredactie), zit Barbara met haar man, twee zonen en aanhang van de oudste in Thailand en probeert Femke met haar gezin het (hopelijk niet zo bloedhete) Frankrijk weer eens uit. We reten schoenen. Volgens Barbara best wel een ding, want vroeger dartelde ze vrolijk rond op hoge hakken, maar door haar moeilijke voeten is een goeie schoen vinden een crime geworden. Femke heeft vrij weinig met schoenen en draagt eigenlijk altijd dezelfde gympen. Ons fragment is geschreven door onze overleden vriendin en collega Els Rozenbroek. Het gaat over euthanasie en de meningen lopen hierover uiteen. Femke vraagt zich af of je Alzheimer niet zijn natuurlijke beloop kunt laten gaan, maar Barbara ziet van dichtbij hoe ontzettend schrijnend dat is. Onze gast is seksualiteitscoach Andrea Davelaar, die ons komt leren hoe je weer zin in een lekker potje vrijen krijgt. Andrea biedt 1:1 coachingstrajecten aan (met de titel 'Stralend in je eigen seksualiteit') Neem snel een kijkje op haar Instagram @ohmygoddesscoach.Adverteren?Wil je adverteren in deze podcast? Stuur dan een mailtje naar adverteren@bienmedia.nl.

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing.  This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod    Licensed under Creative Commons by Attribution 3.0   Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

Die Toedelingswetsontwerp word in die Nasionale Vergadering goedgekeur. Die Wes-Kaapse landbousektor wag in spanning op die 30%-tarief wat op 1 Augustus deur die VSA ingestel word. Ons praat hieroor met die bestuurshoof van Agri Wes-Kaap. Die VSA is 'n tree nader om sanksies teen die ANC-leierskap in te stel.

Rachel Reeves Achieves More Growth, which Could Lead to Yet more Growth! #Podcast UK government borrowing rose by more than expected last month, adding to the pressure on the Chancellor, Rachel Reeves. Analysts say it is increasingly likely that the chancellor will have to raise taxes at the Budget in the autumn, after the government reversed cuts to benefits that had been aimed at saving billions of pounds. The latest borrowing figure was the second-highest June figure since monthly records began in 1993, the ONS added, behind only June 2020, which was heavily affected by the pandemic. MICROCAP CO'S COVERED TODAY: EENERGY #EAAS FONIX MOBILE #FNX HVIVO #HVO NEXTEQ #NXQ SPACEANDPEOPLE #SAL THEWORKS  #WRKS  ***** About The SharePickers Investment Club ***** The SharePickers Investment Club employs a unique, systematic method to uncover small, profitable companies on the London Stock Exchange.  Each potential investment undergoes comprehensive analysis and is evaluated against 15 crucial financial metrics.  This fact-based, quantitative approach allows us to pinpoint high-potential growth businesses and deliver consistent results, bypassing the hype and focusing on the numbers.  *****MY BOOK ***** How to Become a MicroCap Millionaire - A 3 Step Strategy for Stock Market Success  Is now on sale here: https://www.sharepickers.com/how-to-become-a-microcap-millionaire-3-step-strategy/ !!!IF YOU BUY THE BOOK YOU CAN GET 25% OFF MEMBERSHIP TO THE SHAREPICKERS INVESTMENT CLUB!!! The book is £15.39 on Amazon you can get £49.75 back. HOW? If you buy a copy of the book, then like it enough to leave a 5 star rating & write a positive review, you can get yearly membership to the SharePickers Investment Club for just £149.25!!! THIS IS £2.87 WEEK - LESS THAN: HALF A PINT OF BEER A BATTERED JUMBO SAUSAGE FROM THE CHIPPY HALF THE AMOUNT A PERSON SPENDS ON CHOCOLATE ONE FEEDS YOUR MIND THE OTHERS FEEDS YOUR BELLY. —---------------------------------------------------------------------- In this podcast I cover the Microcap News to see if they're good enough to be added to the MicroCap League. The UK's first MicroCap League where 100's of small businesses are analysed and scored in relation to their growth, value, health, efficiency, momentum & potential. The companies that score the highest are added to the MicroCap League and possess the best risk / reward profile. —---------------------------------------------------------------------- If you regularly listen to this podcast and enjoy its output please consider giving it a 5 star rating and review - that way more people will find it. Thank you.

Reaksie op die Minister van Hoër Onderwys en Opleiding se afdanking. Wie is die nuwe minister, Buti Manamela? Die seëvierende Junior Bokke trots terugverwelkom. Vandag, op Wêreld Breindag, is die vinnige toename in demensie-gevalle onder die soeklig. Ons praat met 'n neuroloog.

Barbara zit in Thailand, Gijsje is herstellende van haar borstverkleining, dus deze week is onze co-host: actrice Anniek Pheifer. Anniek heeft net haar propedeuse gehaald van de lerarenopleiding geschiedenis en heeft wat moeite om in vakantiestand te komen. Femke moet even keihard knallen, want haar vakantie begint over een paar dagen. Ze voelt zich overigens vrij belabberd, want is net begonnen aan een hogere dosis Ozempic. We reten monogamie, want wat is het toch lekker om daarover te praten. Anniek pleit voor Monogamie plus amendementen. Dus geen polyamorie, geen vrije relatie, maar heel soms een klein zijpaadje. Ons fragment gaat over docent worden en hoeveel je daarvoor moet oefenen. Anniek is bang dat ze zo ongeveer met pensioen gaat als ze het vak eindelijk in de vingers heeft, maar oh, wat vindt ze het geweldig om voor de klas te staan (en wij denken dat ze een fantastische docent gaat zijn!). Onze gast is Judith Akkerman die de glossy Alle Mooie Borsten lanceerde. Te verkrijgen via allemooieborsten.comSunny CarsKrijg 25 euro korting op je volgende huurauto van Sunny Cars. Ga naar sunnycars.nl/saarpodcast of gebruik de kortingscode SUNNYSAAR. De actiecode is te gebruiken tm 30 september 2025.BOL/KoboOok eindeloos doorlezen? Probeer Kobo Plus nu 30 dagen gratis via bol. Ga naar bol.com/koboplus. ZespriKiezen voor Zespri kiwi's, dat is kiezen voor echt. Wil je nog meer leren over echte voeding en welke gezondheidsvoordelen deze met zich meebrengen? Lees er alles over op (nieuwe pagina) en download het e-book van Zespri. Ga naar Zespri.comAdverteren?Wil je adverteren in deze podcast? Stuur dan een mailtje naar adverteren@bienmedia.nl.

“The proteasome itself, it really helps us unfold or get rid of misfolded proteins or degradations of different cells. We used to have garbage disposals in our sinks, and we used to put food product in there. If your garbage disposal is clogged, then everything backs up. So that's kind of what's really going on in the cell itself, is that I'm building up these unnecessary proteins that we should be getting rid of, and it actually causes apoptosis or cell death,” ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the proteasome inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours (including 40 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 18, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of proteasome inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ Pharmacology 101 series ONS Voice article: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS Guidelines™ and Symptom Interventions Adherence to Oral Anticancer Medication Peripheral neuropathy ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Hematology International Myeloma Foundation Leukemia and Lymphoma Society Multiple Myeloma Research Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we look at the administration, we also want to make sure that we're looking at the blood counts, right? Because proteasome inhibitors are well known for causing thrombocytopenia and neutropenia. So making sure that the patients do meet eligibility for the treatment for that day, and do they have anemia or lower red blood cell counts. You want to make sure that, because of these therapies, that the patient has no symptoms or infections going into each therapy for that day.” TS 10:19 “[Bortezomib], interesting enough, it can cause hypotension, cardiac failure, and sometimes pulmonary edema. Switching that up a little bit, what makes it slightly different, carfilzomib … a lot of times we saw, even in the clinical trial, that there was a lot of hypertension or cardiomyopathies, or arrythmias that we saw with carfilzomib and different dosages that they have indicated from the FDA. So again, monitoring the hypertension … or heart failure.” TS 15:16 “We also want to keep in mind another adverse effect, and especially in myeloma—our patients come in the door already immunocompromised just by the disease state alone. But now I'm giving them therapies that can drop their neutrophil count, so neutropenia and thrombocytopenia, so they are at a higher risk of having serious infections, even including like pneumonia or having outbreaks of herpes zoster or shingles.” TS 16:50 “If the patient has shortness of breath or symptoms, hold the therapy. I think that's one of my biggest messages when it comes to cancer treatments and educating other healthcare providers, or even educating our patients and their caregivers or the care partners with them, is that we need to sometimes hold the therapy for safety.” TS 22:02 “I say keep a log, keep a book. Let me know when the symptoms happen. Are they happening the day of treatment? Are they happening two days later from the treatment? Are they happening a week later from the treatment? And being able to kind of guide which therapy is causing some of these adverse events or side effects alone. So, making them have calendars. When did you take the drug, when did you get your last infusion or your last [subcutaneous] injection? Always talk to your care team, whether it's in the academic center or next to your house in the community.” TS 26:17 “It's us learning how to listen to the patient going forward. We have tasks to do—we all have tasks to do in our lives—but we have to take a breath, be mindful who's in front of us, listen to them first, and then be able to talk to them and care for them upfront and see what the symptoms are. I think that's what we need to do. We have to take a breath in cancer.” TS 39:35

FlySafair tref voorsorgmaatreels ter voorbereiding van 'n dreigende staking deur vlieëniers. Ons praat met die medevoorsitter van die groep van vooraanstaande persone, dr. Roelf Meyer, wat die Nasionale Dialoog sal lei. Op Mandela-dag praat ons oor leierskap, spesifiek verantwoordelike leierskap, of die gebrek daaraan.

De machines rukken op! Of het nou gaat om de smartphone, kunstmatige intelligentie, of dieper nog: de manier waarop we onbewust naar de wereld kijken. Ons hele leven – en zelfs ons mensbeeld – is beïnvloed door de machine. Zijn wij de machines nog de baas, of is het inmiddels andersom? Roderick Nieuwenhuis is daarom terug in De Ongelooflijke. Hij is journalist, historicus en schreef het boek 'Mens en machine'. Het mooie aan Roderick is: hij heeft altijd goede verhalen – én dingen die je nog niet wist. In deze aflevering struinen we door de geschiedenis en literatuur, langs grote denkers, kunstenaars en kantelmomenten. Roderick knoopt het allemaal aan elkaar en eindigt bij een cruciale vraag: wat doet techniek met onze ziel? En hoe gaan we daar goed mee om? Roderick Nieuwenhuis is naast schrijver ook docent journalistiek aan Hogeschool Windesheim. David Boogerd sprak hem samen met onze vaste gast, theoloog Stefan Paas, hoogleraar aan de VU in Amsterdam en de Theologische Universiteit Utrecht.

“We want to make sure that nurses, have opportunities both in our local communities as well as international communities, to engage in courageous dialog with others who may think or look different than we do and whose culture or language may also be different. The difference is what brings us together and allows us to have more of this tapestry of what we are about—ensuring that we advance health for all and that we are able to move forward together,” ONS member Ashley Leak-Bryant, PhD, RN, OCN®, professor at University of North Carolina (UNC) at Chapel Hill, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, chair of the ONS 50th Anniversary Committee, during a conversation about international collaboration in oncology nursing. Burbage spoke with Leak-Bryant, ONS member Kristin Ferguson, DNP, MBA, RN, OCN®, senior director of strategic operations, bone marrow transplant, and cellular therapies at MedStar Georgetown University Hospital, and ONS member and Chief Clinical Officer Erica Fischer-Cartlidge, DNP, RN, AOCNS®, EBP-C, about their experiences working in the global oncology space and how ONS is advancing those efforts. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  ONS Podcast™ ONS 50th anniversary series ONS Voice articles: Bridging Borders and Advancing Oncology's Global Mission Building Collaboration, Education With Oncology Nurses in Malawi Cancer Terms' Negative Associations in African Languages Can Create Communication Barriers for Patients and Clinicians Latest Global Cancer Statistics Underscore the Stark Need to Address Resource-Based Disparities ONS Members Share Resources, Experiences With Philippine Colleagues Clinical Journal of Oncology Nursing articles: Amplifying the Global Impact of Oncology Nursing How Can a Global Experience Enkindle a Passion for Oncology Nursing? Connie Henke Yarbro Oncology Nursing History Center ONS Global Initiatives Joint position statement from ISNCC, MASCC, ONS, AONS, and EONS: Cancer Nursing's Potential to Reduce the Growing Burden of Cancer Across the World Asian Oncology Nursing Society City Cancer Challenge Canadian Association of Nurses in Oncology European Oncology Nursing Society Global Power of Oncology Nursing Health Volunteers Overseas International Society of Nurses in Cancer Care Multinational Association of Supportive Care in Cancer UNC Project Malawi Union for International Cancer Control Email Ashley Leak-Bryant Email Kristin Ferguson Email Erica Fisher-Cartlidge at ONS Global Initiatives To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Leak-Bryant: “My first experience was when I was 21 years old. This was when I was in nursing school at UNC Greensboro. An opportunity came about where I had a chance to go to Honduras, and it was for a one-week service learning cultural immersion experience. And that really gave me my first entree into global health as well as global training. And so, as a first-generation college graduate who had never been out of North Carolina nor had ever flown, it was really an eye-opening experience that has led me now to my current role and passion for global health.” TS 3:24 Leak-Bryant: “In 2018, we had the Malawian delegation come to UNC Chapel Hill. University of North Carolina at Chapel Hill has one of the longest standing collaborations with Malawi, and we call it UNC Project Malawi, and it has been in existence for more than 30 years. … Those nurses and other allied health professionals came to UNC to our cancer center to see how we were making sure that we were engaged in best practices, then how they would be able to take that back to Malawi to make sure that they have what they need as they were opening up a new national cancer Center in Malawi.” TS 7:57 Ferguson: “I have volunteered with ONS at the Asian Pacific Breast Cancer Summit, which was in Indonesia in 2024, and then a few months ago in Singapore. And this is an exciting conference because it draws in nurses from the region, so you end up having five, six, maybe seven countries represented at these conferences, where oncology nurses are very eager to learn, meet one another. And so the teaching that we've provided there has been a combination of lectures and then roundtables where we've strategically placed nurses attending with nurses that are not at their same hospital so that they can connect and share experiences with myself and another ONS member and maybe some other local staff acting as moderators and facilitating conversations.” TS 18:04 Ferguson: “When I was in Tbilisi, Georgia, in 2019, the people there, most of them do not speak English, so they speak their native language Georgian. As I presented, I was wearing a headset, and all of the oncology nurses in the audience were wearing a headset, and I was live translated. What this means is when you're speaking, a translator is sitting in a booth close by and you can actually very quietly hear in your ear he or she quietly translating what you're saying into a language that the nurses can understand. It's actually a bit funny because when you make a joke or ask a question, expecting nods or head shakes, it takes several seconds for the translation to occur. You can get used to a 10-second delay, and you have to pause your speaking and allow actually a little bit more time in presenting if translation services are required.” TS 22:25 Fischer-Cartlidge: “I think that the professional organization role is absolutely critical in how we advance global oncology. Certainly, providing education and helping empower nurses to be more autonomous and equal partners on the care team is a big piece of that. But it's also through forming international partnerships and really elevating the collective voice of nurses in the specialty. This goes a long way in standardizing practices, promoted leadership development among oncology nurses, really across the world. We know that nurses are not seen the same country to country to country on the healthcare team. And so a big part of what we do is try to elevate the importance of what nurses bring to cancer care.” TS 36:14 Fischer-Cartlidge: “I have so many hopes. I hope more opportunities come up for us to raise awareness of this essential role and how we bring a greater spotlight to what nurses are doing across the world for patient care. I hope to see us have more collective global position statements in this space. I hope to see that we have more unified projects across nursing organizations across the world, where we then really can bring our resources and our members together to do great work more effectively and more efficiently. And I think the beginnings of that are happening right up to this point.” TS 41:17  

LES 192Ik heb een functie die God me graag vervullen ziet.Het is je Vaders heilige Wil dat jij Hemzelf compleet maakt, en dat jouw Zelf Zijn heilige Zoon is, voor eeuwig zuiver zoals Hij, uit liefde geschapen en in liefde bewaard, liefde uitbreidend, scheppend in haar naam, voor eeuwig één met God en met jouw Zelf. Maar wat kan zo'n functie betekenen in een wereld vol afgunst, haat en aanval?Daarom heb je een functie in de wereld in haar eigen termen. Want wie kan een taal begrijpen die zijn eenvoudig begrip verre te boven gaat? Vergeving vertegenwoordigt jouw functie hier. Ze is niet Gods schepping, want ze is het middel waarmee onwaarheid ongedaan kan worden gemaakt. En wie zou aan de Hemel vergeving willen schenken? Maar op aarde heb je het middel nodig om illusies los te laten. De schepping wacht louter op jouw terugkeer om te worden erkend, niet om compleet te zijn.Van de schepping valt in deze wereld zelfs geen voorstelling te maken. Ze heeft hier geen betekenis. Vergeving is hetgeen waarmee ze nog het dichtst bij de aarde komen kan. Want in de Hemel ontstaan, heeft ze in het geheel geen vorm. Maar God heeft Iemand geschapen die het vermogen heeft om het totaal vormloze in vorm te vertalen. Wat Hij maakt zijn dromen, maar van een soort zo dicht bij ontwaken, dat het daglicht er al in schijnt, en ogen, die zich al openen, het vreugdevolle schouwspel dat zij bieden aanschouwen.Vergeving beziet mild alles wat onbekend is in de Hemel, ziet het verdwijnen, en laat de wereld achter als een schone, onbeschreven lei waarop het Woord van God de zinloze symbolen die er eerst geschreven stonden, nu vervangen kan. Vergeving is het middel waardoor de angst voor de dood overwonnen wordt, omdat die nu geen hevige aantrekkingskracht meer uitoefent en schuld verdwenen is. Vergeving laat het lichaam zien als wat het is: een eenvoudig leermiddel dat terzijde wordt gelegd wanneer het leren is voltooid, maar hem die leert allerminst verandert.De denkgeest zonder lichaam kan geen vergissingen maken. Hij kan niet denken dat hij sterven zal, of de prooi zal zijn van een genadeloze aanval. Woede wordt onmogelijk en waar blijft dan panische angst? Welke angsten zouden hen nog kunnen bedreigen die de bron van alle aanval, het wezen van leed en de zetel van angst zijn kwijtgeraakt? Alleen vergeving kan de denkgeest ontlasten van de gedachte dat het lichaam zijn thuis is. Alleen vergeving kan de vrede herstellen die God voor Zijn heilige Zoon heeft bestemd. Alleen vergeving kan de Zoon ertoe bewegen weer zijn oog te richten op zijn heiligheid.Wanneer woede verdwenen is, zul je inderdaad ontdekken dat er voor de visie van Christus en de gave van het zien geen offer werd gevraagd, en slechts pijn werd weggenomen van een zieke en gekwelde denkgeest. Is dit onwelkom? Is dit iets om bang voor te zijn? Of is het iets om op te hopen, om dankbaar te begroeten en vol vreugde in ontvangst te nemen? We zijn één en geven daarom niets op. Maar waarlijk is ons alles gegeven door God.Toch hebben we vergeving nodig om te zien dat dit zo is. Zonder haar vriendelijk licht tasten we in het duister rond en gebruiken we ons verstand slechts om onze razernij en aanval te rechtvaardigen. Ons begrip is zo beperkt, dat wat we denken te begrijpen niets anders is dan een uit vergissing voortkomende verwarring. Wij zijn verdwaald in de nevelen van wisselende dromen en angstwekkende gedachten, met onze ogen stijf dichtgeknepen tegen het licht, en onze denkgeest druk bezig met het aanbidden van wat er niet is.Wie kan opnieuw in Christus geboren worden dan hij die ieder die hij ziet, aan wie hij denkt, of die hij zich voorstelt, vergeven heeft? Wie zou bevrijd kunnen worden terwijl hij nog iemand gevangen houdt? Een cipier is niet vrij, want hij zit samen met zijn gevangene vast. Hij moet ervoor zorgen dat die niet ontsnapt en dus brengt hij zijn tijd door met de wacht over hem te houden. De tralies die hem beperken worden de wereld waarin zijn cipier leeft, samen met hem. En van zijn vrijheid hangt de weg naar bevrijding voor hen beiden af.Houd daarom niemand gevangen. Bevrijd in plaats van te binden, want zo word jij bevrijd. De manier is eenvoudig. Telkens wanneer je een steek van woede voelt, besef dan dat je een zwaard boven je eigen hoofd houdt. En het zal vallen of afgewend worden, naargelang je verkiest veroordeeld te worden of vrij te zijn. Op die manier vertegenwoordigt ieder die jou in de verleiding lijkt te brengen om kwaad te worden, jouw verlosser uit de kerker van de dood. En dus ben je hem dank verschuldigd in plaats van pijn.Wees vandaag genadig. De Zoon van God verdient jouw genade. Hij is het die jou vraagt de weg naar de vrijheid nu te aanvaarden. Weiger het hem niet. De Liefde die Zijn Vader hem betoont behoort jou toe. Jouw functie hier op aarde is slechts dat je hem vergeeft, opdat je hem weer als jouw Identiteit aanvaardt. Hij is zoals God hem geschapen heeft. En jij bent wat hij is. Vergeef hem nu zijn zonden en je zult zien dat je één met hem bent.

NESTA EDIÇÃO. Petrobras analisa propostas para serviços de manutenção nas fábricas de fertilizantes do Nordeste. Ministério de Minas e Energia habilita empresa para participar do projeto Poço Transparente, de avaliação do uso de fraturamento hidráulico. ONS pode recomendar retorno do horário de verão para reduzir déficit de potência. Entidades pressionam por aprovação do novo marco do licenciamento ambiental.

No podcast ‘Notícia No Seu Tempo’, confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo’ desta quarta-feira (09/07/2025): Relator na Câmara do projeto de lei que isenta de Imposto de Renda (IR) quem ganha até R$ 5 mil mensais, o deputado Arthur Lira (PP-AL) afirma que a proposta do governo para compensar essa perda arrecadaria mais do que o necessário. Por isso, parlamentares discutem reduzir a alíquota mínima de IR da alta renda de 10% para 9% ou 8%. Segundo Lira, a isenção de IR para quem ganha até R$ 5 mil resultaria em renúncia de R$ 25,8 bilhões. A cobrança de 10% sobre altas rendas arrecadaria R$ 34 bilhões. A proposta do governo é taxar em até 10% quem ganha R$ 1,2 milhão por ano. A tributação, crescente, começaria a partir de quem ganha R$ 600 mil por ano E mais: Economia: IOF rejeitado pode ser compensado no novo IR Política: PF cumpre mandado de busca na Câmara em investigação de fraude Metrópole: Horário de verão poderá ser necessário neste ano, afirma a ONS Internacional: Trump critica Putin, promete armas para Ucrânia e avalia sanções à Rússia Esporte: Cria da base tira Fluminense do MundialSee omnystudio.com/listener for privacy information.

LES 186De verlossing van de wereld hangt af van mij.Dit is de uitspraak die alle arrogantie eens uit elke denkgeest weg zal nemen. Dit is de gedachte van ware nederigheid, die geen andere functie als de jouwe neemt dan degene die jou gegeven is. Het brengt jouw aanvaarding van een jou toegewezen taak met zich mee, zonder aan te dringen op een andere rol. Het velt geen oordeel over de juiste rol voor jou. Het erkent slechts dat de Wil van God op aarde zowel als in de Hemel is geschied. Het verenigt elke wil op aarde in het hemelse plan om de wereld te verlossen en haar terug te voeren tot de hemelse vrede.Laten we onze functie niet bestrijden. Wij hebben die niet vastgesteld. Ze is niet ons idee. De middelen waarmee ze volmaakt zal worden vervuld, zijn ons gegeven. Het enige wat ons wordt gevraagd is dat wij onze taak in oprechte nederigheid aanvaarden en niet met zelfmisleidende arrogantie ontkennen dat we die waardig zijn. Wat ons te doen gegeven is, daartoe hebben we de kracht. Onze denkgeest is volmaakt toegerust om de taak op zich te nemen die ons is toegewezen door Iemand die ons goed kent.Het idee van vandaag lijkt misschien heel ontnuchterend, totdat je de betekenis ervan ziet. Al wat het zegt is dat jouw Vader Zich jou nog steeds herinnert en je het volmaakte vertrouwen schenkt dat Hij in jou heeft als Zijn Zoon. Het vraagt niet dat je op enigerlei wijze anders bent dan jij bent. Wat zou nederigheid anders kunnen vragen dan dit? En wat zou arrogantie anders kunnen weigeren dan dit? Vandaag zullen we ons niet aan onze opdracht onttrekken met de schoonschijnende reden dat bescheidenheid geweld wordt aangedaan. Het is trots om de Roep namens God Zelf te willen ontkennen.Alle valse nederigheid leggen we vandaag naast ons neer, zodat we kunnen luisteren naar Gods Stem, die ons onthult wat Hij ons wil laten doen. We twijfelen niet aan onze geschiktheid voor de functie die Hij ons aanbieden zal. We zijn er alleen zeker van dat Hij onze krachten, onze wijsheid en onze heiligheid kent. En als Hij ons waardig acht, dan zijn we dat. Het is slechts arrogantie om er anders over te oordelen.Er is één manier, en slechts één, om te worden bevrijd uit de gevangenschap die jouw plan om te bewijzen dat het onware waar is, jou heeft gebracht. Accepteer in plaats daarvan het plan dat jij niet hebt gemaakt. Oordeel niet over jouw waarde daarvoor. Als Gods Stem jou verzekert dat de verlossing jouw aandeel nodig heeft en dat het grote geheel van jou afhankelijk is, wees er dan zeker van dat dit zo is. De hoogmoedigen moeten zich wel vastklampen aan woorden, bang als ze zijn die te overstijgen en iets te ervaren wat hun standpunt zou kunnen tarten. Maar de nederigen zijn vrij om de Stem te horen die hun zegt wat ze zijn en wat hun te doen staat.Arrogantie maakt een beeld van jezelf dat niet werkelijk is. Het is dit beeld dat huivert en in doodsangst terugdeinst wanneer de Stem namens God jou verzekert dat jij de kracht, de wijsheid en de heiligheid bezit om alle beelden te overstijgen. Jij bent niet zwak, zoals het beeld van jezelf dat is. Jij bent niet onwetend en hulpeloos. Zonde kan de waarheid in jou niet bezoedelen en ellende kan niet dichtbij Gods heilige woning komen.Dit alles verkondigt jou de Stem namens God. En terwijl Hij spreekt, siddert het beeld en probeert het de bedreiging die het niet kent aan te vallen, terwijl het zijn fundament voelt afbrokkelen. Laat het los. De verlossing van de wereld hangt af van jou en niet van dit hoopje stof. Wat kan het de heilige Zoon van God vertellen? Waarom zou hij er zich überhaupt om bekommeren?En zo vinden we onze vrede. We zullen de functie aanvaarden die God ons gegeven heeft, want alle illusies berusten op de eigenaardige overtuiging dat we voor onszelf een andere kunnen maken. Onze eigengemaakte rollen zijn wisselend en lijken te variëren van rouwdrager tot de extatische gelukzaligheid van liefde en liefhebben. We kunnen lachen of huilen, en de dag begroeten met open armen of met tranen. Ons diepste wezen schijnt te veranderen wanneer we duizend stemmingswisselingen ervaren en onze emoties ons hoog verheffen, of ons in wanhoop neersmakken op de grond.Is dit de Zoon van God? Zou Hij zo'n instabiliteit kunnen scheppen en dat Zoon noemen? Hij die onveranderlijk is deelt Zijn eigenschappen met Zijn schepping. Alle beelden die Zijn Zoon lijkt te maken, hebben geen effect op wat hij is. Ze dwarrelen door zijn denkgeest als door de wind opgewaaide bladeren die een ogenblik een patroon vormen, uit elkaar vallen, zich hergroeperen en wegvliegen. Of als luchtspiegelingen die boven een woestijn worden gezien, oprijzend uit het stof.Deze schimmige beelden zullen verdwijnen en je denkgeest onbeneveld en sereen achterlaten, wanneer jij de functie accepteert die jou gegeven is. De beelden die je maakt laten alleen tegenstrijdige doelen ontstaan die vergankelijk en vaag, onzeker en meerduidig zijn. Wie zou standvastig in zijn pogingen kunnen zijn, en zijn energie en geconcentreerde volharding op zulke doelen kunnen richten? De functies die de wereld hoogacht, zijn zo onzeker dat ze op hun zekerst minstens tien keer per uur veranderen. Welke hoop is er dat er bij zulke doelen iets kan worden gewonnen?In liefdevolle tegenstelling daarmee onderscheidt zich, zo zeker als de zon elke morgen terugkeert om de nacht te verjagen, helder en geheel ondubbelzinnig de jou waarlijk gegeven functie. Over de gegrondheid daarvan bestaat geen twijfel. Ze komt van Iemand die geen vergissingen kent, en Zijn Stem is zeker van Haar boodschappen. Die zullen niet veranderen, noch tegenstrijdig zijn. Ze wijzen alle naar één doel, een dat jij kunt bereiken. Jouw plan is misschien onmogelijk, maar dat van God kan nooit mislukken, omdat het in Hem zijn Oorsprong vindt.Doe zoals Gods Stem aangeeft. En als die iets van jou vraagt wat onmogelijk lijkt, denk er dan aan Wie het is die vraagt, en wie het is die weigert. Overweeg dan dit: wie heeft het ‘t meest waarschijnlijk bij het rechte eind? De Stem die namens de Schepper van alle dingen spreekt, die alle dingen precies kent zoals ze zijn, of een vervormd beeld van jezelf, verward, onthutst, onsamenhangend en onzeker van alles? Laat je niet leiden door die stem. Hoor in plaats daarvan een zekere Stem die jou vertelt van een functie die jou gegeven is door jouw Schepper, die Zich jou herinnert en jou aanspoort dat jij je Hem nu herinnert.Zijn zachte Stem roept vanuit het gekende naar de onwetenden. Hij wil jou troosten, ook al kent Hij geen droefheid. Hij wil een teruggave verlenen ook al is Hij compleet: een gave aan jou, ook al weet Hij dat jij alles al hebt. Hij heeft Gedachten die een antwoord zijn op elke behoefte die Zijn Zoon bespeurt, ook al ziet Hij ze niet. Want Liefde moet geven, en wat in Zijn Naam wordt gegeven neemt die vorm aan welke in een wereld van vormen het meest bruikbaar is.Dit zijn de vormen die nooit kunnen misleiden, omdat ze uit Vormloos heid zelf voortkomen. Vergeving is een aardse vorm van liefde die, zoals ze in de Hemel bestaat, geen vorm bezit. Maar wat hier nodig is wordt hier gegeven zoals het nodig is. In deze vorm kun je zelfs hier je functie vervullen, hoewel wat liefde voor je zal betekenen wanneer vormloosheid jou teruggegeven is, nog grootser is. De verlossing van de wereld hangt af van jou die kan vergeven. Dat is jouw functie hier.

“The five-year relative survival rate for localized, or cancer that is confined to the colon or the rectum, is 91% for colon cancer and 90% for rectal cancer. Distant, metastasized to other organs—the five-year survival rate is 13% for colon and 18% for rectal cancer. So that really shows you the huge difference in screening and where screening can come in and make better outcomes,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer screening. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 4, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Leaners will report an increase in knowledge related to colorectal screening, early detection, and disparities. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episode: Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: AI-Assisted Colonoscopy Can Detect Small Colon Polyps As Colorectal Cancer Incidence Increases in Younger Patients, USPSTF Issues New Screening Guidelines. Here's How Nurses Can Encourage Uptake Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Text Messaging Reduces Disparities in Colorectal Cancer Screening USPSTF Recommends Colorectal Cancer Screening Should Begin at 45 Clinical Journal of Oncology Nursing articles: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Colorectal Cancer Screening: A Quality Improvement Initiative Using a Bilingual Patient Navigator, Mobile Technology, and Fecal Immunochemical Testing to Engage Hispanic Adults Oncology Nursing Forum article: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data ONS Course: Prevention, Detection, and the Science of Cancer—Oncology RN ONS Biomarker Database ONS Colorectal Cancer Learning Library American Cancer Society colorectal cancer resources Colorectal Cancer Alliance To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Interestingly, recent studies suggest that starting screening even earlier than 45, such as age 40, could significantly reduce mortality and incidence rates, especially as colorectal cancer is rising among younger adults.” TS 2:42 “[Artificial intelligence]-enhanced screening tools are also being developed to improve sensitivity, reduce turnaround time, and enable real-time monitoring of disease progression. These innovations aim to make screening more accessible and accurate, especially in our underserved populations. So there's a huge impact on early detection.” TS 4:07 “Those with multiple chronic conditions or limited mobility may be less likely to complete screening, and those results may be harder to interpret. I mentioned a little bit earlier about our underserved or minority populations. Those barriers such as limited health literacy, lack of insurance, and cultural stigma can reduce screening uptake and ultimately follow-through.” TS 12:25 “Patient navigation programs—this is where we have trained navigators to help patients schedule appointments, understand procedures, and ultimately overcome some of these logistical hurdles. These have actually been shown to significantly boost screening rates. Also, those mailed stool-based-test kits—sending those kits directly to a patient home, especially with a personalized letter from a provider to add that extra little touch, has proven effective in increasing participation.” TS 21:29 “Our screening can detect cancer before symptoms appear and even identify precancerous polyps, which can be removed to prevent cancer altogether. Studies actually show that regular screening can reduce colorectal cancer mortality by up to 35% and the incidence of advanced-stage disease by nearly 30%. Just another reason why screening really does matter.” TS 25:53 “Evaluating our implicit bias, especially in something as critical as colorectal cancer, requires both introspection and instructional supports. One way of doing this is by auditing your practice patterns, really looking at reviewing your own screening recommendations and follow-up rates across different patient demographics. So are there certain groups that are less likely to be offered a colonoscopy? I think some of us may have an implicit bias—you see a patient; you're like, ‘There's no way they're going to agree to that, so I'm just not going to offer it.' Where we don't offer it, they don't have that opportunity to decline that. That can lead to further delay. And those patterns can reveal a bias in action.” TS 28:18

Op zaterdag 19 november 2005 gaat de telefoon bij de huisarts van wacht: Willy meldt in paniek dat zijn vrouw Gilberte dood in bed ligt in hun woning in Brecht. De arts komt ter plekke en kan inderdaad enkel nog haar overlijden vaststellen. Er zijn geen uiterlijke sporen van geweld te vinden, maar later dat weekend begint de arts toch te twijfelen. Hij neemt het zekere voor het onzekere en stapt maandagochtend naar de politie. Hier is aflevering 162! Zit je met iets? Praat bij Tele-Onthaal over wat jou bezighoudt. Bel anoniem en gratis naar 106 (24u/7d) of chat via tele-onthaal.be Ons pakketje van €68,99, nu voor €44,99 én ook nog eens gratis verzending als je de code VOLKSJURYBE gebruikt. 35% korting dus en zo aan je voordeur bezorgd. Beter wordt het niet :-). Zolang de voorraad strekt, op = op dus haast je! Surf naar wijnbeurs.be/volksjury of wijnbeurs.nl/volksjury voor Nederlandse luisteraars. Bestel nu op emma-matras.be - Tot 60% korting tijdens de ZOMER SOLDEN (01/07 tot 31/07) Ontvang 5% extra korting met de code DEVOLKSJURY5 Voornaamste bronnen: De Morgen - 'Eerst een groot pak frieten, dan een cognac' De Morgen - 'We gingen naar het bos om te vrijen' De Morgen - Betrapt op moord, net voor crematie van slachtoffer De Morgen - Het gevecht van Yolande Magy, de oudste vrouwelijke gedetineerde van het land De Morgen - Magy blijft hardnekkig betrokkenheid moordpogingen ontkennen De Morgen - Na zeven jaar cel veroordeeld tot zeven jaar cel De Morgen - Tot 25 jaar cel gevorderd voor Magy en Van Gorp De Morgen - Veroordeelde Magy: Liever sterven dan naar gevangenis De Morgen - Yolande gaf me vier pillen, daarmee moest ik Gilberte verdoven De Morgen - Yolande Magy schuldig bevonden aan moordpoging met pillen De Morgen - Yolande Magy wint en mag gevangenis verlaten HBvL - Dochter Magy: “Ik heb indertijd verklaringen afgelegd onder druk omwille van mijn kinderen” HBvL - Magy ontkent bedreigingen en stalking van slachtoffer Gilberte Timmermans HBvL - Oudste vrouwelijke gedetineerde van België na 7 jaar vrijgelaten omdat ze geen eerlijk proces kreeg HBvL - Yolande Magy heeft volgens gerechtspsychiater egocentrische kenmerken HBvL - “Yolande Magy vroeg specifiek naar Zolpidem” HBvL - Zaak-Magy: “Wel degelijk aan Marokkaanse kennis dodende materie gevraagd” HLN - Binnenkort zijn uwe man en uw huis van mijSee omnystudio.com/listener for privacy information.

Vandaag het gesprek met Silvia Oostwegel, Impact ondernemer. Silvia zet zich in voor een sociale en duurzame samenleving als directeur en oprichter van Social Handprint by MAEX en als bestuurder van Social Handprint Foundation. Na een studie biologie en diverse banen in het bedrijfsleven, de overheid en als consultant, is zij als ondernemer gestart om profit en non profit organisaties te helpen hun sociale en duurzame prestaties te meten en te versterken. De missie is maatschappelijke waarden leidend te maken. Laten we beginnen… Wat ik zoal leerde van Silvia: 00:00 intro - 03:05 Waarom heeft een bedrijf de social handprint nodig? 04:05 De maatschappelijke waarden veel meer leidend te maken in je handelen. 05:05 Gestart met werken voor sociale burgerinitiatieven, non profit organisaties. 08:10 een impact economie waarbij je naast de financiële balans ook kijkt naar de impact die je hebt in de samenleving. 11:50 De lastige discussie of je Shell als klant wilt of niet. 13:05 De taal van de corporates gebruiken om euros op te halen om daarmee maatschappelijke investeringen te kunnen doen. 14:20 Ons morele kompas. 20:30 Je hebt ander instrumentarium nodig om duidelijkheid te krijgen wat er maatschappelijke gebeurt met de subsidies. 22:05 Hoe besluit ik, bijvoorbeeld als gemeente, waar mijn geld naartoe gaat? 29:15 Het proces om te bepalen welke projecten geld krijgen. 31:20 Drie verschillende producten, een handprint meting, de impuls (geld), en inzichten in een groep. 33:00 Zo zijn de inkomsten verdeeld. 34:40 De rebranding van de Maatschappelijke AEX. 36:15 Wat is het moment dat je besluit voor de rebranding? 37:00 Van een stichting en BV naar een steward owned bedrijf. 40:25 Nog geen winst gemaakt. 43:40 De dynamische balans tussen de korte en lange termijn van de ondernemer. 45:50 De waarde van de social handprint. 47:00 Regelmatig vernieuwen van de terminologie maakt het lastiger, zoals global goals, armoede, circulair, SDGs, brede welvaart. 51:10 Vertel me wat je doet en wij meten wat je doet. 53:55 Wij vragen nooit of je een beleid hebt op diversiteit, we kijken hoe divers is je organisatie. 54:10 Het gaat niet om de modellen, ga wat doen. Meer over Silvia Oostwegel: https://www.linkedin.com/in/silvia-oostwegel-7101687/  https://www.socialhandprint.com Andere bronnen: IDG Achterhoek community hub Chantal Walg Lokalen Lichtenvoorde Tommy Tomato Oscar Circulair Sustainable Development Goals Brede welvaart Kim Putters Kim Putters: ‘Brede welvaart mét de SDG's: de noodzaak van integrale lange termijnvisie' B corp Code voor sociale ondernemingen PSO - Prestatieladder Socialer Ondernemen Theory of Change Video van het gesprek met Silvia Oostwegel https://youtu.be/5vsC4ZP4BlI Kijk hier https://youtu.be/5vsC4ZP4BlI

Confira nesta edição do JR 24 Horas: A polícia do Rio de Janeiro foi às ruas nesta quinta-feira (3) para prender criminosos das duas maiores facções do país. A operação cumpriu mandados de prisão e de busca e apreensão em quatro estados: Rio de Janeiro, São Paulo, Paraná e Mato Grosso do Sul. Os alvos são integrantes do PCC e do Comando Vermelho, que atuavam juntos no tráfico de drogas e armas no Complexo do Alemão, zona norte do Rio. E ainda: ONS determina aumento do uso de usinas térmicas para o fornecimento de energia no país.

 Critical Thinking  Combatting Domestic Abuse (Part 2) Black Spy Podcast 199, Season 20, Episode 0010 Below is a concise yet data-rich overview of the current domestic violence situation in the UK, as discussed in Part One of the Black Spy Podcast, featuring host Carlton King (“The Black Spy”), neuroscientist Dr Rachel Taylor, and journalist Firgas Esack. Host Carlton King (“The Black Spy”) sits down with Dr Rachel Taylor, a leading neuroscientist, and journalist Firgas Esack, to dive deep into these figures. This episode explores not only the statistics but the human, systemic, and gendered dimensions of domestic violence—shining light on under‑reported experiences, prevention strategies, and why these numbers matter. This is Part Two of an extremely informative series on Combatting Domestic Violence—essential listening for anyone looking to understand and address this crisis in modern Britain.

“Just remember that these patients, these are human beings who had lung cancer. It's a scary disease. And we don't want to just say, ‘Oh, well, that's a horrible disease. They probably won't do well.' These patients are living longer. Our treatments are better. And so no matter who they are, they have every chance of surviving long term for this,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 27, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer survivorship. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Nursing Considerations for Lung Cancer Survivorship Care Nurse-Led Survivorship Programs: Expert Advice to Help You Build Your Institution's Resources Oncology Nursing Forum articles: Empowering Lung Cancer Survivors in Post-Treatment Survivorship Care Using Participatory Action Research A Qualitative Cultural Sensitivity Assessment of the Breathe Easier Mobile Application for Lung Cancer Survivors and Their Families Exploring Stigma Among Lung Cancer Survivors: A Scoping Literature Review ONS Survivorship Care Plan Huddle Card ONS Survivorship Learning Library To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “For patients with stage I disease, they have a pretty good chance of getting to that five-year mark, somewhere probably in the 70%–80% range, depending on if you're stage IA or IB. Then it starts to drop obviously if you go up stages with patients.” TS 6:36 “Our radiation oncologists … and the dosimetrists in radiation oncology do a great job trying to line those beams up to minimize toxicity to those other vital organs. But we just can't always do that. You may see long-term fibrotic changes within the lungs. You could see cardiac damage over time. You can see esophagitis or [gastrointestinal] toxicity, particularly in the esophagus over time, post-radiation. And just the fact of having disease or cancer in the lungs, you can have breathing problems and pulmonary issues long term.” TS 10:37 “Part of survivorship in lung cancer is smoking and smoking cessation. I know it can be hard for people to quit, even people who had curative-intent treatment for their lung cancer—and so keeping up with smoking cessation. And that can be hard again if you don't have access to a smoking cessation specialty or if you live with other people who smoke and don't have really access to programs to help you quit and help you stay quitting.” TS 17:26 “I should talk about autoimmune diseases as part of immunotherapy. We give immunotherapy now in the curative setting preoperatively, postoperatively, post-chemoradiation, so they may get a year or so of immunotherapy. They may develop some sort of autoimmune toxicity from that. Usually that will go away once we stop the immunotherapy. But I've seen some things persist over time. That can go anywhere from like mild eczema that came about to things like more serious, like maybe lupus or scleroderma that may have developed as part of your immunotherapy. And we may stop the immunotherapy, but that may linger on.” TS 25:02  

Podlitiek spring weg met 'n splinternuwe onderhoudreeks! Louis en Arno gesels met Prof Fransjohan Pretorius oor die waarde daarvan om jou geskiedenis te ken. Hy deel ook 'n interessante staaltjie of twee uit die Afrikaner se geskiedenis. Verskoon die swak klankgehalte. (Ons maak maar asof ons doelbewus van ou tegnologie gebruik gemaak het vir die geskiedenis-episode.)Podlitiek word aangebied deur:Louis BoshoffArno RoodtErnst van Zyl

“That's what metastatic breast cancer looks like now—patients can live an extended period of time. And sometimes I think we forget to cheer for stable disease. I tell patients they can live with weeds in their garden; they just can't let the weeds take over their garden. And today we don't have a cure. We live in a rapidly changing time in oncology, and so there's just so much hope right now that we can offer patients,” ONS member Kristi Orbaugh, RN, MSN, RNP, AOCN®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about patient communication in the metastatic breast cancer setting. This podcast episode was developed by ONS through a sponsorship from Lilly. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: Episode 354: Breast Cancer Survivorship Considerations for Nurses Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities ONS Voice articles: Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options What Is HER2-Low Breast Cancer? ONS books: Guide to Breast Care for Oncology Nurses ONS course: Breast Cancer Bundle Oncology Nursing Forum article: Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers ONS Biomarker Database American Cancer Society breast cancer resources METAvivor National Cancer Institute resources: Breast cancer—Patient version To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “I think the most important and vital piece of having those conversations is making sure that we know—really know—that patient, because if we know them, that helps guide what they're needing right then, helps guide our verbiage, helps guide disciplines that we bring in.” TS 2:04 “What do they want to hear? I've been in practice a really, really long time, and I've had the entire spectrum. I've had patients say, ‘Tell me every single detail.' I mean, they want pictures. They want graphs. They want me to draw things. I've even had patients that want me to take markers and mark their body parts. … And then I've had patients that say, ‘I don't want to know anything. I trust my healthcare team. I'm going to proceed with treatment, but I really don't want to know anything.'” TS 3:40 “Remember to make things as simple as possible until we really know what the patient knows. We don't send our children to school and start them out in eighth grade; we send them to kindergarten for a reason. So we get basic information, and then we build on that. And I think we need to remember that when we're doing our patient education, whether it's regarding new chemotherapy or treatment plans or palliative care, we've got to remember to start simple. And maybe we build on that very quickly, or maybe it takes a bit more time. Number one—I actually think it helps with adherence because patients understand what we're asking of them and why we're asking that of them.” TS 12:00 “I think what's really kind of key to keep in mind is that patients are going to seek information. And so, we need to make sure that we're giving them really good, reliable, durable information because if we are not giving them good websites, if we're not giving them good written material, if we're not giving them good verbal information and education, they're going to contact ‘Dr. Google.' Dr. Google is good for a lot of things, but sometimes patients can go down a rabbit hole that's not appropriate or not accurate. That's not a good place for them to be.” TS 14:35 “If we find biomarkers that we call actionable, meaning that we find this mutation and we have a drug that blocks that mutation, that is what is going to guide and drive our treatment. Sometimes that can take a bit of time, right? And if we have a patient and they just find out they have metastatic disease, will they want treatment yesterday. And I understand that. … But frequently there is a very important period of waiting and allowing us to learn that enemy better by reviewing genomic testing, looking at that next-generation sequencing, looking at any positive biomarkers in breast cancer. They may have started out ER/PR positive. Are they still ER/PR positive?” TS 23:46 “I think when we're talking about goals of care, first of all, we need to make sure that the patient understands, when we're talking about metastatic disease today…, this is not a disease that we can cure, but hopefully it's a disease that we can manage for years to come. With that in mind, what's important to that patient? What is important to that patient in terms of life goals? What's important to that patient in terms of toxicities that they will allow and toxicities that they won't allow? TS 29:22 “If don't have a lot of medical knowledge, taking a pill seems less important than getting an IV. It seems like a bigger deal if I would miss getting my IV therapy. ‘Oh, whoops, I forgot to take a pill. Maybe it's not such a big, important piece of my treatment.' So education—when we set that patient down, helping them understand how this drug works, mechanism of action in a simple term, why it's important to take it as scheduled, why it's important to take it with food or without food, why it's important to take it consistently.” TS 34:41

A parade of pauses WAR! Middle East at it again Oracle earnings - wow! Tesla robotaxi spotted PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter ** Look At Album Art ** - So bad  Warm-Up - More pausing floated - We have a CHYNA deal -  kind of - Saying goodbye to Brian Wilson - Tesla - back in buy mode Markets - War! Middle East again (US seems to be helping ?) - Within 2% if ATH and then... - Oracle blows the roof off - UK economy shrinks - bigly ***A NEW Closest to the Pin! Middle East Again - Israel launched a series of airstrikes against Iran early Friday morning local time, targeting locations it said were related to Iran's nuclear program, sparking market fears of a wider conflict. - Mohammad Hossein Bagheri, chief of the Iranian Armed Forces and the country's most senior military official, was killed during the strikes, alongside the commander-in-chief of Iran's Islamic Revolutionary Guard Corps, Hossein Salami, Iranian state media reported. - The Israeli airstrikes also targeted and killed two of Iran's leading nuclear scientists, Fereydoun Abbasi-Davani and Mohammad Mehdi Tehranchi, according to Iranian news outlets. - Odd timing? - Markets initially took it better than expected - until Iran stuck back Valuations - As of the most recent update on June 5, 2025, the forward P/E ratio of the S&P 500 is 21.70. This reflects a decline from 22.44 in the previous quarter and 25.20 one year ago, 10 -year average is about 19 PE Forward Chart Something we discussed on TDI  - Presidential Cycles - The U.S. stock market tends to follow a four-year cycle aligned with presidential terms. Historically, the first year of a president's second term (4 years apart in this case) often mirrors the first year of a new presidency in terms of market behavior—marked by uncertainty, policy re-calibration, and sometimes muted performance - While the first half of the first year can be choppy due to post-election adjustments and early policy moves, the second half—especially Q4—has historically shown stronger performance. This is often attributed to: Stabilizing policy direction after early-year volatility Investor optimism around fiscal planning and budget cycles Seasonal tailwinds like the holiday rally and year-end portfolio rebalancing Presidential Cycle UK Economy- This is why we need to dig further than the headline (more beneath the surface) - The U.K. economy shrank sharply in April as global trade tariffs and domestic tax rises kicked in, data showed Thursday. - The latest monthly growth figures from the Office for National Statistics showed the U.K. economy contracted 0.3% month on month in April, following growth of 0.2% in March. - It was also more than the 0.1% fall economists were expecting. - “After increasing for each of the four preceding months, April saw the largest monthly fall on record in goods exports to the United States with decreases seen across most types of goods, following the recent introduction of tariffs,” --- The real culprit: ----- Domestic tax rises have also been blamed for the steep decline in economic activity. British businesses have been confronted with an increase in national insurance contributions and rise in the minimum age from the start of April, while a temporary tax break on property purchases also came to an end in March. - ----The change in the Stamp Duty Land Tax (paid when buying property or land) in April meant there was a decrease of 63.5% in U.K. residential property transactions from the previous month, the ONS noted, with buyers rushing to complete purchases before the tax break ended. US Economy - U.S. consumer prices increased less than expected in...

Episode 367: Pharmacology 101: PARP Inhibitors “We know that in cells that are proliferating very quickly, including cancer cells, single-strand DNA breaks are very common. When that happens, these breaks are often repaired by the PARP enzyme, and the cells can continue their replication process. If we block PARP, that repair cannot happen. So in blocking that, these single-strand breaks then lead to double-strand breaks, which ultimately is leading to cell apoptosis,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the PARP inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 13, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of PARP inhibitors in cancer care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 232: Managing Fatigue During PARP Inhibitor Maintenance Therapy Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Maintenance Therapy ONS Voice articles: PARP Inhibitors and Ovarian Cancer Genomics May Trick PARP Inhibitors to Treat More Cancers Oncology Drug Reference Sheet: Niraparib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing articles: PARP Inhibition: Genomics-Informed Care for Patients With Malignancies Driven by BRCA1/BRCA2 Pathogenic Variants Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers Oncology Nursing Forum article: Familiarity and Perceptions of Ovarian Cancer Biomarker Testing and Targeted Therapy: A Survey of Oncology Nurses in the United States Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Biomarker Database ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The big toxicities here to watch for are primarily hematologic toxicities. It is one of those targeted therapies that does affect blood cell counts. So I'd say the blood cell count that is most commonly affected here is the hemoglobin. So, anemia very frequent complication that we see, probably a little bit more with olaparib compared with other drugs, but we see it as a class side effect. And we can also see neutropenia and thrombocytopenia with these agents, probably a little bit more with niraparib versus the others, but again, you can see it across all of these drugs.” TS 8:16 “We mentioned that rare risk of MDS and AML. This isn't a particularly scary thing if you talk to patients about it. Because of the rarity that we see this, it isn't something that we need to overemphasize, but I think careful monitoring of blood counts in is stressing the importance of that and early intervention here is very important.” TS 16:55 “This is a collaborative effort. And because of the home administration here, these patients do need to be followed very closely. So we are not laying eyes on them usually with the frequency that we do when we have patients actually coming into our infusion centers for treatments—so making sure that there is a plan for regular follow-up with these patients to ensure that they're getting that lab work done, that that's being looked at closely, that we're adjusting the dose if we need to based on that lab work, that we are managing the patient's fatigue. Again, that potentially dose reductions may be needed if patients are having that extreme fatigue.” TS 19:34 “I think one of those [misconceptions] could be that they're only effective in patients that have that BRCA1/2 mutation. And again, remember here that there is some data in particular disease states that we can use them and that they work in the absence of those mutations.” TS 25:12

“[My mom] would always be very inspirational whenever I would see her studying so long. And when she finally got to be a nurse, I always admired her vocation and compassion with her patients. She would always go above and beyond for all of her patients. I also got inspired a lot by my brother, as well, just seeing how passionate he was for caring for his patients for the families as well, and helping them deal with the any grief or loss that they were experiencing, Carolina Rios, MSN, RN, CPhT, told Valerie Burger, RN, MA, MS, OCN®, CPN, member of the ONS 50th anniversary planning committee, during a conversation about families in nursing. Burger spoke with Carolina, her mother Lissette Gomez-Rios, MSN, APRN, AGACNP-BC, FNP-BC, OCN®, BMTCN®, and her brother Carlos Rios, BSN, RN, BMTCN®, about how having multiple nurses in their family has affected them personally and professionally. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: 50th anniversary series Episode 327: Journey of a Student Nurse: Choosing Oncology Nursing and the Value of a Professional Home ONS Voice articles: Innovation Inspires Hope: A Nurse's Journey of Passion and Purpose When Health Care Is Woven in Our Family Fabric, We Find Support in Unexpected Places Is Work–Life Balance Possible? The Evidence Says It Isn't—Rather, It's About Reframing Our Thinking ONS Nurse Well-Being Learning Library Oncology Nursing Foundation Resiliency Resources Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Lissette: “Being in the oncology nursing as a family, when I feel the necessity to talk to them, they listen to me. They pay attention, and we help each other to cope, especially when there is a loss of our patients, so we help each other. We are understanding. We give them compassion and the advice that we need.” TS 6:51 Carlos: I remember growing up—and [my mom] would always be in school and in the healthcare field, so I knew growing up I wanted to be in the healthcare field. She was the one that guided me into going to nursing because at a certain point, I wasn't sure what I was going to be doing. She guided me, and once I started doing nursing, this has been the career I want to do, I want to continue doing. I'm very grateful for her guiding me into nursing.” TS 9:48 Carolina: “Anytime I had a question I would ask them. They would always help me out, make sure I really understood. It would actually be a little funny because sometimes they would overexplain, and I was a little overwhelmed, and I would have to be like, ‘OK, let's dial it back. Let's get back to the basics.'” TS 14:22  

“From a radiation standpoint, the biggest thing we're looking at is the treatment site, the dosage, and the way the radiation has been delivered. There are different ways that we can focus radiation using methods such as intensity-modulated radiotherapy, volumetric modulated arc therapy, flattening radiation beams, and proton beam therapy to try to help minimize radiation exposure to healthy tissues to minimize patient risk for secondary cancers,” ONS member Andrea Matsumoto, DNP, AGACNP-BC, AOCNP®, radiation oncology nurse practitioner at Henry Ford Health in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation-associated secondary cancers. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 30, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to radiation-associated secondary cancers. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 12: The Intersection of Radiation and Medical Oncology Nursing  ONS Voice articles: Even Low-Dose CT Radiation Increases Risk for Hematologic Cancers in Young Patients Nurse-Led Survivorship Programs: Expert Advice to Help You Build Your Institution's Resources Secondary Cancers in Pediatric Survivors: Increased Risk and Unique Barriers to Care ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Radiation Therapy Certificate™ Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: Adolescent and Young Adult Cancer Survivors: Development of an Interprofessional Survivorship Clinic ONS Radiation Learning Library ONS Survivorship Learning Library American Cancer Society survivorship resources National Coalition for Cancer Survivorship National Comprehensive Cancer Network survivorship guidelines To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “It's hypothesized that radiation can also induce different DNA mutations in healthy cells or in tissues surrounding cancers that we're treating, including alterations in the structure of signal genes or chromosomes, or also causing changes in gene expression, which may help develop a neoplasia or a cancer in a patient's future. The development of cancer carcinogenesis that is impacted or caused by radiation has to do with the chemicals that are produced, the impact it has on cell proliferation, and how these changes and mutations can also pass on to daughter cells in the future as cells are replicating.” TS 2:34 “Younger people are much more susceptible to having a secondary cancer, especially because we know with treatments, we expect them to live a longer time. And once patients get to 5 and 10 years out from radiation is when we may see a secondary cancer develop. We also have seen research showing that females may be more sensitive to some of the carcinogenic effects of radiation. Underlying diseases and genetic mutations can also impact patients' risk.” TS 5:27 “I think a big thing is remembering that although the risk is really small, the risks does exist, and so it's something that we want to bring up with patients. And even if it is something 20 years down the line for a child being treated and making sure that this information is written down somewhere. So when reviewing records, anyone from a care provider to a family member might be able to say, ‘Okay, I see that, and I'm going to keep that on my radar.' And that's another big benefit of using NP- and nurse-led survivorship clinics and creating survivorship care plans.” TS 17:20